Skip to main content

Yuri Fedoriw, MD, is a UNC Lineberger Comprehensive Cancer Center member involved in the UNC Project-Malawi Cancer Program. His research interests focus on the immunologic and genetic mechanisms of lymphomagenesis, particularly in the setting of HIV infection.

LabCorp Distinguished Professor, Pathology & Lab Medicine
Vice Chair for Clinical Research and Academic Affairs
Co-director, UNC Project-Malawi Cancer Program
Global Cancer Pathology Director, Institute for Global Health and Infectious Disease
UNC-Chapel Hill
Clinical Research

Area of Interest

Since 2011, I have been involved in the UNC Project-Malawi Cancer Program, developing and supporting diagnostic services in support of the Kamuzu Central Hospital Lymphoma Study, AIDS Malignancy Consortium and NIH-funded clinical trials. I now serve as the co-Director of the UNC Project-Malawi Cancer Program, the co-PI of the UNC-Malawi-South Africa Cancer Consortium (U54CA254564) and direct the translational lymphoma studies of samples submitted to UNC through this ongoing work. We have established weekly diagnostic telepathology conferences between Malawian pathologists and clinical teams to improve diagnostic accuracy and build regional capacity for cancer care. We support training in global cancer research through the recently awarded Malawi Cancer Outcomes Research Program (D43CA260641 Fedoriw, MPI) that aims to develop global cancer research leaders in Malawi and UNC.

My research interests focus on the immunologic and genetic mechanisms of lymphomagenesis, particularly in the setting of HIV infection. While hematologic malignancies and lymphoproliferative disorders (including Multicentric Castleman Disease) in sub-Saharan Africa arise under intrinsic and extrinsic pressures very different from those in the United States, comprehensive analyses of these diseases have not been performed. Our laboratory group uses advanced sequencing, immunophenotypic and cellular analyses to address gaps in our understanding of lymphomagenesis and tumor microenvironment in the context of HIV-associated immune dysregulation. Deciphering these tumor-host interactions is critical to better tailor treatment and improve outcomes, particularly in the era of cancer immunotherapy.

My clinical efforts revolve around the diagnosis and classification of benign and malignant hematolymphoid disorders. I served as the Director of Hematopathology at UNC from 2012-2019, and previously as the Director of the Hematopathology Fellowship Program. I have served on the NCI Lymphoma Clinical Trials Planning Group and the Hematology and Clinical Microscopy Committee for the College of American Pathologists. I am a member of the United States and Canadian Academy of Pathology Education Committee.

Find publications on PubMed

News and Stories

View all related posts

Headshot of Yuri Fedoriw.